Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease - Wikidata - wikimedia - TriplyDB

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

http://www.wikidata.org/entity/Q34995066

about

Aclidinium bromide for the treatment of chronic obstructive pulmonary disease Aclidinium bromide for stable chronic obstructive pulmonary disease Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis Positioning new pharmacotherapies for COPD Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.Pharmacotherapies for COPD.Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006 - 2010).The Genuair® inhaler: a novel, multidose dry powder inhaler.Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.Clinical use of aclidinium in patients with COPD.The role of aclidinium bromide in the treatment of chronic obstructive pulmonary disease.Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression.Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date Long-acting muscarinic antagonists.The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPD.Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).Recent advances in the management of chronic obstructive pulmonary disease.Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.Emerging Therapeutic Options for the Management of COPD.Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.

P2860

Q22306019-D5E7AF4D-7DAE-47D8-B35E-9AD3FA12D70F Q24193506-DBCAD238-C54C-41BC-9B80-20AADBE7BA1B Q24197853-E14B4148-AFBC-4525-A86B-DFC39F3532E3 Q26798659-AB2157AC-BF8F-4F32-8CF1-97731064D1D9 Q27022636-233CA5CB-8E00-4E74-81FE-2E8AB1CC571F Q27023223-4F8F6355-F4A6-48E9-994C-8DCEF5DFA1BC Q28070274-B5597583-F11C-40E3-B58E-FF45C18A32E8 Q28070325-5ECC812A-0A0E-4AA2-8DF4-40CDAB87C874 Q34336907-043B787A-3630-497B-90D6-5E56591837D3 Q34944547-312E1C36-A371-4FF6-AE74-72FBC4ECB1E3 Q35268320-2640C834-9C49-4D3E-AB69-A89A8B049702 Q35538249-3A3F7A85-3F9E-451B-8A0D-2F23F1E691D3 Q35584046-515030B1-6A9B-458B-AE5F-B008F4945670 Q35875281-D8473486-7FDE-4783-8540-F6A48F590290 Q35914818-FE3F8461-BE97-4232-9010-88F64B6D8D1A Q36307097-BB001312-F1A4-47CD-BE2A-5816D0B79F99 Q36843717-DFFAB131-50B0-4C7A-8599-8A316EED14AC Q37278903-28671CB6-AF59-4426-AD01-C72BEF660824 Q37894102-A7A4BF9F-C362-4885-B07D-8F10C70448F8 Q37984784-1FBB5A2D-782C-4967-BBF0-1E32C41074C4 Q38051307-1115010D-6A56-4DFC-A7E3-BBD37C01725D Q38052955-535AABF6-91C7-404E-A5CD-A3E265CDEEF4 Q38066977-79FBE90A-8A74-46F9-977F-40CB15231EE7 Q38069580-94D395DE-3EB8-433E-B030-8478DE3DC7FD Q38112092-38CABDF5-A6A9-4F55-AF39-571483B1D6A6 Q38131050-BB73319E-D533-4CC6-97E5-A0D68C343C2C Q38210538-76FEBA52-1F7B-48F1-A909-252F10FE1AC8 Q38287153-5C69DE01-CDD2-4D0D-AE99-FEA0FB6F432F Q38317463-FAC3E430-7E01-4F4C-9BF2-F33FE1085E23 Q38432438-5F482455-688F-4415-B093-75B12391EB70 Q38537326-18942C49-86C0-41DD-8283-C5B99D987FAA Q38592062-C53BCEB9-F5AC-407F-BD16-CB1304A377B5 Q38604644-EDEA70F7-1A07-4B81-99C1-7B452B96F604 Q38660895-C1DEF0A5-BE18-406F-A415-15CC1DE36F68 Q38701325-57975EB5-A9DE-4497-8E49-5641E386D694 Q39399389-EBB604B0-1BA9-44B4-9281-7C77456B5F62 Q39936577-1CD24793-F596-45B5-A03C-2D68DC38164B Q41400495-F8B1EA53-4B89-42FF-851B-33DA192D5BE6

P2860

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

http://www.wikidata.org/entity/Q34995066

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

@ast

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

@en

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

@nl

type

label

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

@ast

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

@en

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

@nl

prefLabel

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

@ast

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

@en

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

@nl

P1433

Q34995066-09C808BB-E21A-4693-A6D8-8363CA8FBF1F

P1476

Q34995066-EC5120C3-AC7A-41E5-8F9D-44AAEE99D0F7

P2093

Q34995066-160215CC-EA1E-45F0-A2EC-9BA2802DD867

Q34995066-19FEAE8D-8122-4AEA-931D-31C808A2A7EE

Q34995066-1EF57CC4-03EF-433C-B87F-202124256B8D

Q34995066-85D953CB-5E58-4CA3-8AEE-2733A1EFFB02

Q34995066-8A39B45C-3806-43EB-A537-FC8522AC167C

Q34995066-8F50B79E-00A6-4462-92D9-418F32951167

Q34995066-AE8BB563-F7F3-42FB-84DC-AB8D6E889F43

Q34995066-B2983222-B21B-4EBD-B1EB-0B9DF24F70A8

Q34995066-EC507659-A79A-495A-8413-5E856D46F660

Q34995066-FA64431A-C172-4882-9339-5B8E8F8F0036

P2860

Q34995066-11A4D150-76E3-4D35-8A90-4244FD6F049E

Q34995066-17E09634-6F23-4C76-BC4E-259388A35330

Q34995066-26472EA3-6A18-4BF3-8DAF-B2F4E17FE823

Q34995066-2DB9FCCE-84FE-410C-868F-4BEC6F5737FF

Q34995066-2E113A1A-67F3-4277-BCCD-2CFD27229AA9

Q34995066-2F39A5D9-B75E-4C7F-93D5-65B0CB09E644

Q34995066-38058BDD-22D6-408D-967C-E03EC8ACA7FF

Q34995066-380FEB2D-18A9-492A-8AE9-6DE1812B6F12

Q34995066-485BAB40-A318-4E41-A9D8-4B0F872BF6A5

Q34995066-5D6C58A0-DF83-49AD-A0C8-C16D2B789935

P2888

Q34995066-5B1399D3-4C0E-4D49-BFC2-704980C235C5

P304

Q34995066-C99C267A-6C53-4CD9-8FAB-E51894F05090

P31

Q34995066-D2A3BA64-A2A1-49C1-9FE3-744222D31F55

P356

Q34995066-E2189072-C46A-438E-868C-13CF7657EFFE

P478

Q34995066-6650E3D7-B1C1-48B6-8F01-191ECC61D6EB

P50

Q34995066-73878F25-AF97-444B-A0C7-E848BC84AD16

P577

Q34995066-5160AF19-D0C7-4B86-B6CB-3BCD2ECFCA5E

P5875

Q34995066-A8AC52B7-1990-4598-9A75-C2E95B9A3CDA

P6179

Q34995066-8C65E138-127F-4B27-89C1-566890BCA5D3

P698

Q34995066-BFFFF187-5790-4B3B-A4C9-3385671CE498

P921

Q34995066-813C574E-EA6A-4224-AD19-6C999F78D767

P932

Q34995066-1E0F50EE-92BC-4169-BC34-9209E63F8185

P356

1465-9921-12-55

P1433

Respiratory Research

P1476

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

@en

P2093

Alvar Agusti

http://www.w3.org/2001/XMLSchema#string

Cynthia Caracta

http://www.w3.org/2001/XMLSchema#string

Eric D Bateman

http://www.w3.org/2001/XMLSchema#string

Esther Garcia Gil

http://www.w3.org/2001/XMLSchema#string

Helgo Magnussen

http://www.w3.org/2001/XMLSchema#string

James F Donohue

http://www.w3.org/2001/XMLSchema#string

Nicholas J Gross

http://www.w3.org/2001/XMLSchema#string

Pascal Chanez

http://www.w3.org/2001/XMLSchema#string

Paul W Jones

http://www.w3.org/2001/XMLSchema#string

Rosa Lamarca

http://www.w3.org/2001/XMLSchema#string

P2860

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

Standardisation of spirometry

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

The effect of tiotropium on exacerbations and airflow in patients with COPD.

Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

The role of anticholinergics in chronic obstructive pulmonary disease.

P2888

1465-9921-12-55

P304

55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1465-9921-12-55

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Leonardo M Fabbri

P577

2011-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51075417

http://www.w3.org/2001/XMLSchema#string

P6179

1013179762

http://www.w3.org/2001/XMLSchema#string

P698

21518460

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

P932

3098801

http://www.w3.org/2001/XMLSchema#string